Investigation of reduced glycopeptid susceptibility among methicillin resistant staphylococci

被引:1
作者
Gunes, Hayati [1 ]
Cetin, Emel Sesli [2 ]
Kaya, Selcuk [2 ]
Aridogan, Buket Cicioglu [2 ]
机构
[1] Namik Kemal Univ, Fac Med, Dept Med Microbiol, Tekirdag, Turkey
[2] Suleyman Demirel Univ, Fac Med, Dept Med Microbiol, TR-32200 Isparta, Turkey
关键词
Staphylococci; meticillin resistance; glycopeptid susceptibility; vancomycin intermediate Staphylococcus aureus (VISA); vancomycin hetero-intermediate Staphylococcus aureus (h-VISA); AUREUS HETEROGENEOUSLY RESISTANT; VANCOMYCIN; EPIDEMIOLOGY; EMERGENCE; STRAINS;
D O I
10.5897/AJMR11.1445
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Incidence of vancomycin intermediate Staphylococcus aureus (VISA) and vancomycin hetero-intermediate Staphylococcus aureus (h-VISA) has been increasing in the world and our country. We aimed to determine whether there is any difference between the minimal inhibitory concentration (MIC) of glycopeptide antibiotics against meticillin susceptible and resistant staphylococci and investigate the prevalence of VISA and h-VISA among Staphylococcus aureus strains. 60 MRSA, MSSA, MRCNS and MSCNS isolated in our laboratory between April 2007-2008, were included in this study. Bacteria were inoculated onto a BHI agar supplemented with 6 mu g/ml vancomycin, strains which have shown growth on screen agar were evaluated for being VISA/hVISA by determining PAP-AUC ratio. Vancomycin and teicoplanin MIC values of the strains were determined by microdilution and E-test methods. Two of MRSA strains which grew on screen agar were excepted as suspicious VISA/h-VISA and they were confirmed as h-VISA by PAP-AUC method. Among all strains, methicillin resistant strains showed higher MIC values for glycopeptides than methicillin susceptible strains. We suggested that clinicians should be aware of h-VISA and VISA strains which are being increasingly reported in the world. More clinically supported multisentric studies must be performed in our country to clarify these prevalence rates and determine the clinical relevance of this resistance profile.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 28 条
[1]  
Aktas E, 2010, MIKROBIYOL BUL, V44, P339
[3]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P565
[4]  
Clinical Laboratory Standards Institute, 2009, PERF STAND ANT SUS S
[5]   Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus [J].
Gould, Ian M. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 31 :1-9
[6]  
Gulay Z., 1998, ANKEM DERG, V12, P101
[7]  
Guleroglu S., 2002, ANKEM DERG, V16, P457
[8]  
Hanaki H, 2001, Methods Mol Med, V48, P85, DOI 10.1385/1-59259-077-2:85
[9]   Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [J].
Hiramatsu, K ;
Aritaka, N ;
Hanaki, H ;
Kawasaki, S ;
Hosoda, Y ;
Hori, S ;
Fukuchi, Y ;
Kobayashi, I .
LANCET, 1997, 350 (9092) :1670-1673
[10]   Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [J].
Hiramatsu, K ;
Hanaki, H ;
Ino, T ;
Yabuta, K ;
Oguri, T ;
Tenover, FC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :135-136